Progyny, Inc. (NASDAQ:PGNY - Get Free Report) CEO Peter Anevski bought 209,500 shares of the firm's stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now owns 441,463 shares of the company's stock, valued at $6,392,384.24. This trade represents a 90.32 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
NASDAQ:PGNY traded up $0.18 during trading hours on Thursday, reaching $14.71. 1,918,778 shares of the company were exchanged, compared to its average volume of 1,423,054. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 1.64 and a beta of 1.35. The stock has a 50 day simple moving average of $15.27 and a 200 day simple moving average of $20.63. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08.
Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same quarter in the previous year, the firm posted $0.16 EPS. The business's revenue was up 2.0% compared to the same quarter last year. On average, analysts predict that Progyny, Inc. will post 0.59 EPS for the current fiscal year.
A number of equities analysts recently commented on PGNY shares. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $17.00 target price (down previously from $22.00) on shares of Progyny in a research note on Monday, December 2nd. Bank of America cut their price target on shares of Progyny from $22.00 to $21.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of Progyny in a research report on Tuesday, October 1st. Truist Financial reissued a "hold" rating and set a $19.00 price objective (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Finally, Canaccord Genuity Group dropped their target price on Progyny from $18.00 to $17.00 and set a "hold" rating on the stock in a report on Wednesday, November 13th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $25.00.
Check Out Our Latest Analysis on Progyny
Large investors have recently modified their holdings of the business. Pacer Advisors Inc. lifted its position in shares of Progyny by 12,579.4% during the third quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company's stock worth $41,777,000 after purchasing an additional 2,472,983 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in Progyny by 1,576.0% in the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company's stock worth $42,991,000 after acquiring an additional 2,412,068 shares during the last quarter. Invenomic Capital Management LP acquired a new position in Progyny in the third quarter valued at approximately $29,509,000. Farallon Capital Management LLC boosted its position in Progyny by 120.8% during the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company's stock valued at $37,436,000 after purchasing an additional 715,900 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Progyny by 530.4% during the third quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after acquiring an additional 594,140 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.